Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPRT1 | P00492 | 7/20 | 0.42 |
| ▸ | NOS1 | P29475 | 5/20 | 0.34 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.33 |
| ▸ | ALB | P02768 | 1/20 | 0.33 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.33 |
| ▸ | PNP | P00491 | 3/20 | 0.33 |
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.32 |
| ▸ | NOS3 | P29474 | 1/20 | 0.32 |
| ▸ | NOS2 | P35228 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4898608 | 0.85 | HPRT1 (0.40) | HPRT1NOS1PNPTLR7NOS3 | |
| SCHEMBL4890592 | 0.85 | HPRT1 (0.40) | HPRT1NOS1PNPTLR7NOS3 | |
| SCHEMBL6448839 | 0.82 | HPRT1 (0.39) | HPRT1NOS1PNP | |
| SCHEMBL18480838 | 0.81 | NR1I2 (0.38) | NR1I2ALBPDE4D | |
| SCHEMBL23587737 | 0.79 | — | — | |
| SCHEMBL9310753 | 0.79 | HPRT1 (0.46) | HPRT1NOS1NOS3NOS2 | |
| SCHEMBL18480732 | 0.78 | NR1I2 (0.37) | NOS1NR1I2ALBPDE4DNOS3 | |
| SCHEMBL23587705 | 0.77 | NR1I2 (0.35) | NR1I2ALBPDE4D | |
| SCHEMBL23587615 | 0.77 | NR1I2 (0.35) | NR1I2ALBPDE4D | |
| SCHEMBL23587628 | 0.77 | NOS1 (0.36) | NOS1NR1I2ALBPDE4DNOS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070025964-A1 | HIV-1 mutations selected for by beta-2',3'-didehydro-2',3'-dideoxy-5-fluorocytidine | EMORY UNIVERSITY | 2007-02-01 | — | — | US | claimed |
| EP-1731155-A2 | Beta-D-2', 3' -Didehydro-2',3' -Dideoxy-5-Fluorocydine for use in the treatment of HIV infections | EMORY UNIVERSITY (US) | 2006-12-13 | — | — | EP | claimed |
| EP-0805683-B1 | 5-FLUORO-2',3'-UNSATURATED-PYRIMIDINE NUCLEOSIDES | UNIV EMORY (US) | 2005-12-28 | — | — | EP | claimed |
| US-20040082552-A1 | HIV-1 mutations selected for by beta-2',3'-didehydro-2',3'-dideoxy-5-fluorocytidine | EMORY UNIVERSITY | 2004-04-29 | — | — | US | claimed |
| JP-2002535278-A | — | — | 2002-10-22 | — | — | JP | claimed |
| CN-1337880-A | HIV-1 mutations selected by beta-2 ', 3' -didehydro-2 ', 3' -dideoxy-5-fluorocytidine | UNIV EMORY (US) | 2002-02-27 | — | — | CN | claimed |
| EP-1143976-A2 | BETA-D-2', 3' -DIDEHYDRO-2', 3' -DIDEOXY-5-FLUOROCYTIDINE FOR USE IN THE TREATMENT OF HIV INFECTIONS | EMORY UNIVERSITY (US) | 2001-10-17 | — | — | EP | claimed |
| US-6232300-B1 | ADMINISTERING AS HEPATITIS B VIRICIDE | EMORY UNIVERSITY | 2001-05-15 | — | — | US | claimed |
| WO-2000043014-A2 | BETA-D-2',3'-DIDEHYDRO-2',3'-DIDEOXY-5-FLUOROCYTIDINE FOR USE IN THE TREATMENT OF HIV INFECTIONS | EMORY UNIVERSITY (US) | 2000-07-27 | — | — | WO | claimed |
| CN-101239063-A | Pharmaceutical compositions | GLAXO GROUP LTD (GB) | 2008-08-13 | — | — | CN | disclosed |
| CN-101219148-A | Beta-d-2', 3' -didehydro-2', 3' -dideoxy-5-fluorocytidine for use in the treatment of HIV infections | UNIV EMORY (US) | 2008-07-16 | — | — | CN | disclosed |
| US-20060084627-A1 | Synergistic interaction of abacavir and alovudine | MEDIVIR AB (SE) | 2006-04-20 | — | — | US | disclosed |
| EP-1536800-B1 | SYNERGISTIC INTERACTION OF ABACAVIR AND ALOVUDINE | MEDIVIR AB (SE) | 2006-01-04 | — | — | EP | disclosed |
| EP-0805683-B1 | 5-FLUORO-2',3'-UNSATURATED-PYRIMIDINE NUCLEOSIDES | UNIV EMORY (US) | 2005-12-28 | — | — | EP | disclosed |
| US-5049671-A | Hepatitis, AIDS | BURROUGHS WELLCOME CO. (US) | 1991-09-17 | — | — | US | disclosed |
| US-5034394-A | Therapeutic nucleosides | BURROUGHS WELLCOME CO. (US) | 1991-07-23 | — | — | US | disclosed |
| EP-0434450-A2 | Therapeutic nucleosides | THE WELLCOME FOUNDATION LIMITED (GB) | 1991-06-26 | — | — | EP | disclosed |
| WO-1991000282-A1 | THERAPEUTIC NUCLEOSIDES | THE WELLCOME FOUNDATION LIMITED (GB) | 1991-01-10 | — | — | WO | disclosed |
| EP-0366385-A1 | Guanine derivatives having antiviral activity and their pharmaceutically acceptable salts | THE WELLCOME FOUNDATION LIMITED (GB) | 1990-05-02 | — | — | EP | disclosed |
| EP-0349242-A2 | Therapeutic nucleosides | THE WELLCOME FOUNDATION LIMITED (GB) | 1990-01-03 | — | — | EP | disclosed |